Looking to the future, emerging life sciences technologies will drive the industry, enabling a new wave of scientific understanding and therapies developed for patients with conditions once thought impossible to treat. With an eye toward the future of life sciences technology, BroadOak has built a team and a network of key opinion leaders with the experience and knowledge in Cell and Gene therapy, Single Cell, Bioprocess, and Life Sciences Software. BroadOak executives serve on the boards of leading life sciences companies and organizations, including MD Bio, Science and Medicine Group, and Slone Partners. As one of the most active investors in the space, BroadOak combines financial expertise and deep knowledge of the life sciences industry to offer investment companies and advisory clients a compelling value proposition.
Learn more about BroadOak’s most recent industry engagement:
Once a year, we welcome founders, investors, and stakeholders for several days to discuss the latest trends and developments in the life sciences tools, diagnostics, and biopharma services industries. Unstructured time is built in so entrepreneurs, investors, and experts can make valuable connections. Our fifth Investor Day was held in April of 2022.
Over 60 CEOs, Life Sciences Industry Executives, and Investors participated
Held a think tank on Cell & Gene Therapy focused on the latest industry trends and opportunities
Presentations by several portfolio companies
BroadOak delivered financial market and Fund updates
Hosted a panel on Single Cell Genomics moderated by BroadOak Vice President Aaron Fisher. The Panel included Stevan Jovanovich, CEO of S2 Genomics, Sepehr Kiani, CEO of Fluent Bio, Joe Mellor, CSO of SeqWell, and Jim Flannigon, CEO of Honeycomb Bio.
The International Society for Cell & Gene Therapy (ISCT) annual meeting attracts investors, entrepreneurs, and thought leaders from around the world. BroadOak Operating Partner Bryan Poltilove led a panel discussion on strategies to attract capital for CGT tools and technologies businesses at the 2022 meeting.
BroadOak knows the life sciences tools and services industry inside and out. From start to finish, our relationship has been a true partnership.
Managing Director | Antibodies-Online
We invest in and advise life sciences companies with a focus on Cell and Gene Therapy, Single Cell Genomics, and Life Sciences Software.